[ad_1]
ProShare Advisors LLC acquired a new position in shares of Pulmonx Co. (NASDAQ:LUNG – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 10,669 shares of the company’s stock, valued at approximately $72,000.
A number of other hedge funds and other institutional investors have also made changes to their positions in the business. BNP Paribas Financial Markets purchased a new position in shares of Pulmonx during the 4th quarter worth about $43,000. Stifel Financial Corp purchased a new position in shares of Pulmonx during the 4th quarter worth about $81,000. SG Americas Securities LLC lifted its holdings in shares of Pulmonx by 27.0% during the 4th quarter. SG Americas Securities LLC now owns 15,555 shares of the company’s stock worth $106,000 after acquiring an additional 3,310 shares during the period. Graham Capital Management L.P. lifted its holdings in shares of Pulmonx by 73.3% during the 4th quarter. Graham Capital Management L.P. now owns 18,071 shares of the company’s stock worth $123,000 after acquiring an additional 7,641 shares during the period. Finally, Wells Fargo & Company MN raised its holdings in Pulmonx by 48.7% in the fourth quarter. Wells Fargo & Company MN now owns 18,418 shares of the company’s stock valued at $125,000 after buying an additional 6,033 shares during the period. Hedge funds and other institutional investors own 91.04% of the company’s stock.
Insider Buying and Selling at Pulmonx
In related news, Director Glendon E. French III sold 20,000 shares of the firm’s stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $7.85, for a total transaction of $157,000.00. Following the sale, the director now directly owns 991,974 shares in the company, valued at $7,786,995.90. This trade represents a 1.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 6.80% of the company’s stock.
Pulmonx Price Performance
NASDAQ:LUNG opened at $3.18 on Wednesday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.77 and a current ratio of 7.70. The company has a 50-day moving average of $4.49 and a 200-day moving average of $6.01. Pulmonx Co. has a 52 week low of $2.83 and a 52 week high of $9.37. The company has a market capitalization of $128.02 million, a price-to-earnings ratio of -2.21 and a beta of 0.65.
Pulmonx (NASDAQ:LUNG – Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.01. The firm had revenue of $22.54 million for the quarter, compared to analysts’ expectations of $22.03 million. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. As a group, equities research analysts anticipate that Pulmonx Co. will post -1.55 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several research analysts recently commented on LUNG shares. Piper Sandler restated an “overweight” rating and issued a $9.00 price target (down previously from $10.00) on shares of Pulmonx in a report on Thursday, May 1st. Canaccord Genuity Group dropped their price objective on shares of Pulmonx from $16.00 to $15.00 and set a “buy” rating on the stock in a research note on Thursday, May 1st. Citigroup dropped their price objective on shares of Pulmonx from $6.50 to $4.15 and set a “neutral” rating on the stock in a research note on Thursday, May 22nd. Morgan Stanley started coverage on shares of Pulmonx in a research note on Monday, March 10th. They set an “equal weight” rating on the stock. Finally, Jefferies Financial Group started coverage on shares of Pulmonx in a research note on Monday, March 10th. They set a “buy” rating on the stock. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $11.59.
Check Out Our Latest Research Report on LUNG
Pulmonx Company Profile
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
Featured Articles
Want to see what other hedge funds are holding LUNG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pulmonx Co. (NASDAQ:LUNG – Free Report).
Receive News & Ratings for Pulmonx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pulmonx and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
Source link
